Subtle blood-brain barrier leakage rate and spatial extent: Considerations for dynamic contrast-enhanced MRI: Considerations

Medical Physics

Volumn 44, Issue 8, 2017, Pages 4112-4125

  Van De Haar, Harm J ^a,b   Jansen, Jacobus F A ^a,b   Jeukens, Cécile R L P N ^a   Burgmans, Saartje ^a,b   Van Buchem, Mark A ^c   Muller, Majon ^c   Hofman, Paul A M ^a,b   Verhey, Frans R J ^a,b   Van Osch, Matthias J P ^c   Backes, Walter H ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; blood brain barrier; brain MRI; dynamic contrast enhanced MRI, leakage; pharmacokinetic modeling

Indexed keywords

BLOOD; GRAPHIC METHODS; NEURODEGENERATIVE DISEASES;

ALZHEIMERS DISEASE; BLOOD-BRAIN BARRIER; BRAIN MRI; DYNAMIC CONTRAST ENHANCED MRI; DYNAMIC CONTRAST-ENHANCED MRI, LEAKAGE; LEAKAGE RATES; PHARMACOKINETIC MODELING; SCAN TIME; SPATIAL EXTENT; WHITE MATTER;

DYNAMIC CONTRAST ENHANCED MRI;

GADOBUTROL; CONTRAST MEDIUM;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CLINICAL ARTICLE; COMPUTER SIMULATION; CONTRAST TO NOISE RATIO; CONTROLLED STUDY; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; GRAY MATTER; HEMATOCRIT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PLASMA VOLUME; SIGNAL NOISE RATIO; WHITE MATTER; NUCLEAR MAGNETIC RESONANCE IMAGING;

BLOOD-BRAIN BARRIER; CONTRAST MEDIA; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; WHITE MATTER;

EID: 85022320223     PISSN: 00942405     EISSN: 24734209     Source Type: Journal    
DOI: 10.1002/mp.12328     Document Type: Article

References (36)

1. Erickson MA, Banks WA,. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab. 2013; 33: 1500-1513.
2. Wardlaw JM, Smith C, Dichgans M,. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013; 12: 483-497.
3. Sourbron S, Ingrisch M, Siefert A, Reiser M, Herrmann K,. Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI. Magn Reson Med. 2009; 62: 205-217.
4. Zlokovic BV,. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. Neuron. 2008; 57: 178-201.
5. Larsson HBW, Courivaud F, Rostrup E, Hansen AE,. Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T1-weighted MRI at 3 tesla. Magn Reson Med. 2009; 62: 1270-1281.
6. Cramer SP, Larsson HBW,. Accurate determination of blood-brain barrier permeability using dynamic contrast-enhanced T1-weighted MRI: a simulation and in vivo study on healthy subjects and multiple sclerosis patients. J Cereb Blood Flow Metab. 2014; 34: 1655-1665.
7. Khalifa F, Soliman A, El-Baz A, et al., Models and methods for analyzing DCE-MRI: a review. Med Phys. 2014; 41: 124301.
8. van de Haar HJ, Burgmans S, Hofman PAM, Verhey FRJ, Jansen JFA, Backes WH,. Blood-brain barrier impairment in dementia: current and future in vivo assessments. Neurosci Biobehav Rev. 2015; 49C: 71-81.
9. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw JM,. Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res-Neuroimaging. 2009; 171: 232-241.
10. Armitage PA, Farrall AJ, Carpenter TK, Doubal FN, Wardlaw JM,. Use of dynamic contrast-enhanced MRI to measure subtle blood-brain barrier abnormalities. Magn Reson Imaging. 2011; 29: 305-314.
11. Barnes SR, Ng TSC, Montagne A, Law M, Zlokovic BV, Jacobs RE,. Optimal acquisition and modeling parameters for accurate assessment of low K trans blood-brain barrier permeability using dynamic contrast-enhanced MRI. Magn Reson Med. 2016; 75: 1967-1977.
12. Taheri S, Gasparovic C, Huisa BN, et al., Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke. 2011; 42: 2158-2163.
13. Taheri S, Gasparovic C, Shah NJ, Rosenberg GA,. Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping. Magn Reson Med. 2011; 65: 1036-1042.
14. Bronge L, Wahlund L-OO,. Contrast-enhanced MRI of White Matter Lesions in Patients with Blood-Brain Barrier Dysfunction. Dement Geriatr Cogn Disord. 2000; 11: 477-481.
15. Montagne A, Barnes SR, Sweeney MD, et al., Blood-Brain Barrier Breakdown in the Aging Human Hippocampus. Neuron. 2015; 85: 296-302.
16. van de Haar HJ, Burgmans S, Jansen JFA, et al., Blood-brain barrier leakage in early Alzheimer's disease. Radiology. 2016; 281: 527-535.
17. Jelescu IO, Leppert IR, Narayanan S, Araújo D, Arnold DL, Pike GB,. Dualoral resolution dynamic contrast-enhanced MRI protocol for blood-brain barrier permeability measurement in enhancing multiple sclerosis lesions. J Magn Reson Imaging. 2011; 33: 1291-1300.
18. Fischl B, Salat DH, Busa E, et al., Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002; 33: 341-355.
19. de Boer R, Vrooman HA, van der Lijn F, et al., White matter lesion extension to automatic brain tissue segmentation on MRI. NeuroImage. 2009; 45: 1151-1161.
20. Haroon HA, Buckley DL, Patankar TA, et al., A Comparison of Ktrans Measurements Obtained with Conventional and First Pass Pharmacokinetic Models in Human Gliomas. J Magn Reson Imaging. 2004; 19: 527-536.
21. Li KL, Zhu XP, Waterton J, Jackson A,. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging. 2000; 12: 347-357.
22. Lavini C, Verhoeff JJC,. Reproducibility of the gadolinium concentration measurements and of the fitting parameters of the vascular input function in the superior sagittal sinus in a patient population. Magn Reson Imaging. 2010; 28: 1420-1430.
23. Pintaske J, Martirosian P, Graf H, et al., Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006; 41: 213-221.
24. Patlak CS, Blasberg RG, Fenstermacher JD,. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983; 3: 1-7.
25. Aerts HJWL, Jaspers K, Backes WH,. The precision of pharmacokinetic parameters in dynamic contrast-enhanced magnetic resonance imaging: the effect of sampling frequency and duration. Phys Med Biol. 2011; 56: 5665-5678.
26. Zar JH,. Biostatistical Analysis, 4th edn. Prentice Hall; 1999.
27. McGrath DM, Bradley DP, Tessier JL, Lacey T, Taylor CJ, Parker GJM,. Comparison of model-based arterial input functions for dynamic contrast-enhanced MRI in tumor bearing rats. Magn Reson Med. 2009; 61: 1173-1184.
28. Wardlaw JM, Sandercock PAG, Dennis MS, Starr J,. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. 2003; 34: 806-811.
29. Choyke PL, Dwyer AJ, Knopp MV,. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2003; 17: 509-520.
30. Lee MH, Smyser CD, Shimony JS,. Resting-state fMRI: a review of methods and clinical applications. Am J Neuroradiol. 2013; 34: 1866-1872.
31. Woo C-W, Krishnan A, Wager TD,. Cluster-extent based thresholding in fMRI analyses: pitfalls and recommendations. NeuroImage. 2014; 91: 412-419.
32. Heye AK, Culling RD, Valdés Hernández MDC, Thrippleton MJ, Wardlaw JM,. Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. Neuroimage Clin. 2014; 6: 262-274.
33. Heye AK, Thrippleton MJ, Armitage PA, et al., Tracer kinetic modelling for DCE-MRI quantification of subtle blood-brain barrier permeability. NeuroImage. 2016; 125: 446-455.
34. Cao Y, Li D, Shen Z, Normolle D,. Sensitivity of Quantitative Metrics Derived from DCE MRI and a Pharmacokinetic Model to Image Quality and Acquisition Parameters. Acad Radiol. 2010; 17: 468-478.
35. Kershaw LE, Cheng HLM,. Temporal resolution and SNR requirements for accurate DCE-MRI data analysis using the AATH model. Magn Reson Med. 2010; 64: 1772-1780.
36. Seelig A, Gottschlich R, Devant RM,. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci USA. 1994; 91: 68-72.